Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge

被引:25
作者
Canthaboo, C
Xing, D
Wei, XQ
Corbel, MJ
机构
[1] Natl Inst Biol Stand & Controls, Div Bacteriol, Potters Bar EN6 3QG, Herts, England
[2] Univ Glasgow, Dept Bacteriol & Immunol, Glasgow G11 6NT, Lanark, Scotland
关键词
D O I
10.1128/IAI.70.2.679-684.2002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The mechanism whereby whole-cell pertussis vaccines (WCV,) confer protection against Bordetella pertussis is still not fully understood. We have previously, reported that macrophage activation produced by vaccination with WCV is associated with induction of NO synthesis by macrophages in response to in vitro stimulation with B. pertussis antigens. To determine whether NO production is an effector of protection or simply a marker of activation, the susceptibility of inducible nitric oxide synthase (type II, iNOS) knockout mice to infection with B. pertussis was examined. We showed that iNOS knockout mice were more susceptible to B. pertussis respiratory challenge than wild-type mice. iNOS-deficient mice also developed a less effective protective response than wild-type mice after the same immunization with WCV. This suggests that NO plays an important role in effecting protection against B. pertussis challenge.
引用
收藏
页码:679 / 684
页数:6
相关论文
共 24 条
[1]   THE RESPIRATORY BURST OF PHAGOCYTES [J].
BABIOR, BM .
JOURNAL OF CLINICAL INVESTIGATION, 1984, 73 (03) :599-601
[2]  
BECKERMAN KP, 1993, J IMMUNOL, V150, P888
[3]  
DING AH, 1988, J IMMUNOL, V141, P2407
[4]   UPTAKE AND INTRACELLULAR SURVIVAL OF BORDETELLA-PERTUSSIS IN HUMAN MACROPHAGES [J].
FRIEDMAN, RL ;
NORDENSSON, K ;
WILSON, L ;
AKPORIAYE, ET ;
YOCUM, DE .
INFECTION AND IMMUNITY, 1992, 60 (11) :4578-4585
[5]   SPECIFIC AMINO-ACID (L-ARGININE) REQUIREMENT FOR THE MICROBIOSTATIC ACTIVITY OF MURINE MACROPHAGES [J].
GRANGER, DL ;
HIBBS, JB ;
PERFECT, JR ;
DURACK, DT .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (04) :1129-1136
[6]   A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis [J].
Greco, D ;
Salmaso, S ;
Mastrantonio, P ;
Giuliano, M ;
Tozzi, AE ;
Anemona, A ;
Atti, MLCD ;
Giammanco, A ;
Panei, P ;
Blackwelder, WC ;
Klein, DL ;
Wassilak, SGF ;
Stefanelli, P ;
Bottone, M ;
Sofia, T ;
Luzi, S ;
Bellomi, G ;
Cobianchi, F ;
Canganella, G ;
Meduri, F ;
Scuderi, G ;
Chiarini, A ;
Maggio, M ;
Taormina, S ;
Genovese, M ;
Moiraghi, A ;
Barale, A ;
DiTommaso, S ;
Malaspina, S ;
Vasile, E ;
Ferraro, P ;
DalLago, P ;
DeMarzi, L ;
Robino, L ;
Giraldo, E ;
Coppola, N ;
Materassi, P ;
Castellani, GT ;
Basso, F ;
Barbuti, S ;
Quarto, M ;
Lopalco, P ;
DOrazio, P ;
Sanguedolce, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (06) :341-348
[7]   A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine [J].
Gustafsson, L ;
Hallander, HO ;
Olin, P ;
Reizenstein, E ;
Storsaeter, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (06) :349-355
[8]  
Huang FP, 1998, EUR J IMMUNOL, V28, P4062, DOI 10.1002/(SICI)1521-4141(199812)28:12<4062::AID-IMMU4062>3.0.CO
[9]  
2-K
[10]  
JAMES SL, 1989, J IMMUNOL, V143, P4208